Embecta Corp

NASDAQ EMBC

Download Data

Embecta Corp EBITDA for the Trailing 12 Months (TTM) ending March 31, 2024: USD 232.80 M

Embecta Corp EBITDA is USD 232.80 M for the Trailing 12 Months (TTM) ending March 31, 2024, a -23.32% change year over year. EBITDA, or Earnings Before Interest, Taxes, Depreciation, and Amortization, measures a company's operating performance by excluding non-operating expenses.
  • Embecta Corp EBITDA for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 303.60 M, a -36.84% change year over year.
  • Embecta Corp EBITDA for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 480.70 M, a 90.30% change year over year.
  • Embecta Corp EBITDA for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 252.60 M.
NASDAQ: EMBC

Embecta Corp

CEO Mr. Devdatt Kurdikar
IPO Date April 1, 2022
Location United States
Headquarters 300 Kimball Drive, Parsippany, NJ, United States, 07054
Employees 2,200
Sector Healthcare
Industry Medical instruments & supplies
Description

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

Similar companies

ANGO

AngioDynamics Inc

NA

NA

AKYA

Akoya Biosciences Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email